Log inSign up
user avatar
Akari Therapeutics
@AkariTX
Akari Therapeutics ($AKTX) is a biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer.
akaritx.com
Joined March 2018
115
Following
365
Followers
  • user avatar
    Akari Therapeutics
    @AkariTX
    Jan 16, 2025
    #WELCOME to Akari’s Social Channels! Hear directly from recently appointed CEO, Samir Patel, MD, and why he is excited about the future of Akari. Follow us and visit akaritx.com to learn more. #AKTX #AntibodyDrugConjugates #ADC #Oncology bit.ly/4jhavfg
    245K
  • user avatar
    Akari Therapeutics
    @AkariTX
    Feb 13, 2023
    Akari announces that based on FDA feedback, the Phase 3 clinical trial of nomacopan in pediatric HSCT-TMA is advancing into pivotal, registrational Part B study sooner than expected in two of three age cohorts and the addition of a new development program in adult HSCT-TMA $AKTX
    1.1K
  • user avatar
    Akari Therapeutics
    @AkariTX
    Aug 1, 2022
    Akari announces prioritization of Phase 3 clinical trial of nomacopan in severe pediatric HSCT-TMA, with Part A data expected in 1H of 2023, and the promising pre-clinical program of PAS-nomacopan in GA that has generated positive pre-clinical results. akaritx.com/2022/08/01/aka…
  • user avatar
    Akari Therapeutics
    @AkariTX
    Jan 8, 2020
    Our team will be attending the J.P. Morgan Healthcare Conference in San Francisco. We look forward to kicking off a new year with everyone there #JPM20 akaritx.com
  • user avatar
    Akari Therapeutics
    @AkariTX
    May 10, 2022
    #bullouspemphigoid is a rare and severe autoimmune skin disease associated with high mortality. At @Akari we aspire to change this for patients. Phase II results of nomacopan in BP were published in @JAMADerm and the Ph III clinical trial is enrolling:
    investor.akaritx.com
    Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the...
  • user avatar
    Akari Therapeutics
    @AkariTX
    Mar 2, 2022
    We are pleased to announce the appointment of Rachelle Jacques as the new President and CEO of Akari Therapeutics, effective end of March 2022. Read the full release here: investor.akaritx.com/news-releases/… $AKTX
    investor.akaritx.com
    Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer | Akari...
  • user avatar
    Akari Therapeutics
    @AkariTX
    Aug 12, 2020
    We are pleased to announce our successful end-of-phase II meeting with the @US_FDA to initiate a pivotal phase III study for treatment of #BullousPemphigoid with #nomacopan - see the full details here: investor.akaritx.com/news-releases/…
  • user avatar
    Akari Therapeutics
    @AkariTX
    Sep 23, 2022
    Tomorrow is aHUS Awareness Day and @Akari stands with all people who have life-threatening TMAs. The Phase 3 Part A clinical trial of #nomacopan in severe pediatric HSCT-TMA, a rare #TMA with an 80% mortality rate and no approved treatments, is currently underway. @aHUS24Sept
  • user avatar
    Akari Therapeutics
    @AkariTX
    Jan 27, 2020
    Today we're pleased to announce positive preclinical data supporting PAS-nomacopan as a potential treatment option for back-of-the-eye diseases #nomacopan - see the full details here: investor.akaritx.com/news-releases/…
  • user avatar
    Akari Therapeutics
    @AkariTX
    Nov 10, 2022
    Akari today announced the #FDA has granted the Rare Pediatric Disease Designation to nomacopan for the treatment of pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy #HSCT-TMA. $AKTX
  • user avatar
    Akari Therapeutics
    @AkariTX
    Aug 31, 2020
    Nomacopan’s dual complement (C5) and leukotriene (LTB4) inhibition blocks several key inflammatory pathways that drive #COVID19 #pneumonia. We believe this inhibition of multiple inflammatory pathways distinguishes nomacopan from other potential therapies focused on a single MOA.
  • user avatar
    Akari Therapeutics
    @AkariTX
    Jan 27, 2020
    Replying to @AkariTX
    Wynne Weston-Davies, Medical Director, Akari Therapeutics, said, “We are now actively exploring other pre-clinical models in diseases such as AMD and how best to develop these findings in the clinic where there remains a significant unmet need.”
  • user avatar
    Akari Therapeutics
    @AkariTX
    Feb 24, 2021
    Bullous pemphigoid (BP) is a severe and rare autoimmune inflammatory blistering skin disease. Learn more about BP here: pemphigus.org/pemphigoid/ #RareDiseaseDay #RDD21 #bullouspemphigoid
  • user avatar
    Akari Therapeutics
    @AkariTX
    Aug 31, 2020
    Clinical studies both underway and planned for patients with #COVID19 #pneumonia in the U.S., U.K., and Brazil with nomacopan